ストックスクリーナーアプリを入手
14.01
0.78%
0.010
前日終値:
$14.02
開ける：
$14.14
24時間の取引高:
8,288
Relative Volume:
0.04
時価総額：
$476.42M
収益：
$99.53M
当期純損益:
$-21.57M
株価収益率:
-21.59
EPS:
-0.6488
ネットキャッシュフロー:
$-9.84M
1週間 パフォーマンス:
-4.33%
1か月 パフォーマンス:
-8.60%
6か月 パフォーマンス:
-1.46%
1年 パフォーマンス:
+63.92%
1日の値動き範囲:
$13.88
$14.14
1週間の範囲:
$13.56
$15.28
52週間の値動き範囲:
$8.61
$19.60
Neuropace Inc Stock (NPCE) Company Profile
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
13.88 | 502.51M | 99.53M | -21.57M | -9.84M | -0.6488 |
ABT
Abbott Laboratories
|
114.75 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.92 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.36 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.62 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.54 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-21 | 開始されました | UBS | Buy |
| 2024-03-14 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 開始されました | Leerink Partners | Outperform |
| 2023-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-24 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 開始されました | Lake Street | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 開始されました | Robert W. Baird | Outperform |
| 2021-05-17 | 開始されました | JP Morgan | Overweight |
| 2021-05-17 | 開始されました | Morgan Stanley | Overweight |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Neuropace Inc (NPCE) 最新ニュース
HC Wainwright Has Positive Outlook of NeuroPace Q3 Earnings - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for NeuroPace - MarketBeat
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayTrend Following Picks - Vinanet
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? - TradingView
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - TradingView
Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock - Investing.com
Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock By Investing.com - Investing.com UK
Cantor Fitzgerald Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $21 - Moomoo
GSA Capital Partners LLP Acquires Shares of 115,535 NeuroPace, Inc. $NPCE - MarketBeat
NeuroPace (NPCE): OrbiMed reports 1.51M-share, 4.4% beneficial stake - Stock Titan
H.C. Wainwright Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
NeuroPace Q2 revenue up 21% to USD 22.8M - Medical Buyer
Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NeuroPace (NASDAQ:NPCE) Shares Gap DownHere's Why - MarketBeat
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $19 - Moomoo
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up - Yahoo Finance Singapore
NeuroPace, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Neuropace earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Technical Reactions to NPCE Trends in Macro Strategies - Stock Traders Daily
NeuroPace Inc.: Q2 Earnings Snapshot - aol.com
NeuroPace Q2 Earnings Call Highlights - MarketBeat
NeuroPace Raises FY26 Sales Guidance Above Estimates - scanx.trade
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance - Investing News Network
NPCE: Q2 revenue up 17% to $22.8M; guidance raised; IGE FDA review ongoing with positive outlook - TradingView
NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
NPCE: Revenue up 17% with strong RNS growth; guidance raised; IGE approval path remains active - TradingView
Earnings call transcript: NeuroPace tops Q2 2026 estimates, shares slip after hours - Investing.com
NeuroPace Q2 EPS beats estimates as revenue rises 17% to $22.8 million - scanx.trade
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo! Finance Canada
NeuroPace, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
NeuroPace Inc 2Q 2026: Revenue $22.8M, Net loss $(6.2M), EPS $(0.18) — 10-Q Summary - TradingView
NeuroPace, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NeuroPace, Inc. Revises Earnings Guidance for the Full Year of 2026 - marketscreener.com
Neuropace Inc (NASDAQ: NPCE) Share Price, NPCE Stock News, NPCE Share Price & Updates - Kalkine
Enterprise value to EBIT forward of Neuropace, Inc. – NASDAQ:NPCE - TradingView
NeuroPace, Inc. expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Neuropace Inc (NPCE) Stock News Today - TradingKey
Neuropace, Inc. (NPCE) Stock Analysis: A 45% Potential Upside Awaits Investors - DirectorsTalk Interviews
Earnings Preview: NeuroPace to Report Financial Results Post-market on August 11 - Moomoo
NeuroPace (NPCE) Expected to Release Earnings on Tuesday - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
NPCE Q1 2026 Earnings: Narrower Net Loss Beats Expectations as Shares Decline 6.25%ROIC Trend Report - Vinanet
NPCE Q1 2026 Earnings: Narrower Loss Beats Estimates by 14.75%, Yet Shares Slip 6.25%Diluted EPS Report - Vinanet
Trading the Move, Not the Narrative: (NPCE) Edition - Stock Traders Daily
Neuropace, Inc. Revenue Breakdown – NASDAQ:NPCE - TradingView
Neuropace Inc (NPCE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cantor Fitzgerald Initiates NeuroPace(NPCE.US) With Buy Rating, Announces Target Price $21 - Moomoo
HC Wainwright Reaffirms Buy Rating for NeuroPace (NASDAQ:NPCE) - marketbeat.com
H.C. Wainwright reiterates Buy on NeuroPace stock after FDA feedback By Investing.com - Investing.com Nigeria
NeuroPace stock tumbles as FDA declines epilepsy expansion By Investing.com - Investing.com Australia
Neuropace Inc (NPCE) 財務データ
収益
当期純利益
現金流量
EPS
0.59%
0.75%
大文字化:
|
ボリューム (24 時間):